In the world of scientific research and drug development, CAS No. 1620056-47-4 is a significant component in the synthesis of Lenacapavir, a novel HIV-1 capsid inhibitor currently in clinical trials as a potential treatment for HIV-1 virus. Below is a comprehensive guide that will provide an in-depth look into the various aspects of CAS No. 1620056-47-4 Lenacapavir intermediate.What is CAS No. 1620056-47-4 Lenacapavir Intermediate?CAS No. 1620056-47-4 is the chemical formula for the intermediate compound used in the synthesis of Lenacapavir, which is an investigational drug designed to treat HIV-1 virus in patients. The intermediate molecule is a key component that has a critical impact on the effectiveness and potency of the final drug product.The Synthesis of LenacapavirThe synthesis of Lenacapavir involves several chemical steps, and CAS No. 1620056-47-4 is an essential building block in this process. It is used to create ring systems and other structural features in the final drug compound. Subsequently, Lenacapavir can be produced in large quantities through a series of reactions and purification methods.Chemical Properties of CAS No. 1620056-47-4 Lenacapavir IntermediateCAS No. 1620056-47-4 chemical compound has unique physicochemical properties such as a molecular weight of 580.8 g/mol, a melting point of 138-142 °C, and a solubility range between DMF, DMSO, and water. These properties are vital in understanding the compound’s behavior and interactions in manufacturing and product development processes.Importance in HIV-1 Clinical TrialsLenacapavir has been in clinical studies since 2018 as a novel inhibitor drug for the treatment of HIV-1 virus in patients. The role of CAS No. 1620056-47-4 in Lenacapavir’s structure and formation is critical in determining its effectiveness and safety in clinical use.Challenges in Synthesizing LenacapavirDespite the successful demonstration of Lenacapavir’s high potency and activity against HIV-1 virus, there have been challenges to develop and scale up the synthesis process. One bottleneck in the process is the availability and quality of the CAS No. 1620056-47-4 intermediate compound, which requires precise control of critical reaction parameters to obtain desired quality and purity.CAS No. 1620056-47-4 Lenacapavir Intermediate SuppliersWell-established chemical companies provide CAS No. 1620056-47-4 for academic research and pharmaceutical drug development purposes. These suppliers ensure high-quality intermediate compounds that meet stringent safety requirements and are produced under strict regulation and documentation. Some notable vendors for this intermediate include AK Scientific, ChemFaces, and Xcess Biosciences.Applications in Other Drug DevelopmentCAS No. 1620056-47-4 Lenacapavir intermediate has the potential for use in applications beyond HIV-1 treatment. Its structure and properties can be utilized as intermediates for synthesizing other drugs that are under development in the pharmaceutical industry. Many of these drugs have a similar structure to Lenacapavir, opening up the possibility of discovering new drug candidates for various diseases and illnesses.Future Prospects of CAS No. 1620056-47-4 Lenacapavir IntermediateWith Lenacapavir in phase II and III clinical trials, ongoing research and development of other drug candidates that use CAS No. 1620056-47-4 are expected to increase. Scientists and researchers will continue to explore the properties of this intermediate compound, hoping to leverage its unique features to develop new treatments and cures for various diseases and illnesses.ConclusionCAS No. 1620056-47-4 Lenacapavir intermediate is an essential molecule in the synthesis of the Lenacapavir drug, which is currently being studied as a potential treatment for HIV-1 virus. Characteristics such as structure, chemical properties, and quality are vital in understanding the compound’s behavior and interactions in the drug manufacturing process. Despite the challenges, ongoing research and development are expected to leverage the compound's properties to create new drugs for other types of diseases and illnesses.Quote InquiryContact us!

Introduction: Lenacapavir 2109226-54-0Lenacapavir 2109226-54-0 is a novel antiretroviral drug currently in development for the treatment of HIV/AIDS. It works by inhibiting the maturation of the capsid, a protein shell that encloses the virus's genetic material, thereby preventing the virus from replicating and infecting new cells.Mechanism of ActionThe unique mechanism of action of Lenacapavir 2109226-54-0 sets it apart from currently available antiretroviral drugs, which primarily target the reverse transcriptase and protease enzymes of HIV. By inhibiting capsid maturation, Lenacapavir 2109226-54-0 offers a new strategy for combating HIV/AIDS and has the potential to overcome existing treatment resistance.Clinical TrialsLenacapavir 2109226-54-0 has shown promising results in early-stage clinical trials. In a phase 1b trial, a single dose of Lenacapavir 2109226-54-0 reduced viral load by up to 0.5 log10 in people living with HIV who were already on stable antiretroviral therapy. Phase 2/3 trials are currently underway to evaluate the safety and efficacy of multiple doses.Potential BenefitsThe development of Lenacapavir 2109226-54-0 represents a significant advancement in the treatment of HIV/AIDS. It offers a new mechanism of action, potential for long-acting formulation, and effectiveness against drug-resistant strains of HIV. Moreover, because it targets the capsid, which is highly conserved across HIV types, Lenacapavir 2109226-54-0 has the potential to be effective against all strains of the virus.Safety ProfileLenacapavir 2109226-54-0 appears to be generally safe and well-tolerated. In clinical trials, no serious adverse events related to Lenacapavir 2109226-54-0 have been reported. Further studies will be needed to fully evaluate its safety profile.Formulation and AdministrationLenacapavir 2109226-54-0 is currently being developed as a long-acting injectable treatment. This formulation offers several potential benefits, including better adherence, fewer side effects, and improved outcomes for people living with HIV/AIDS. Future developments may include oral formulations or combination therapies with other antiretroviral drugs.Current Status and Future OutlookLenacapavir 2109226-54-0 is still in development and has not yet been approved by regulatory agencies for use in the treatment of HIV/AIDS. However, based on the promising results of early clinical trials, it has the potential to become a game-changer in the field of HIV/AIDS treatment.ConclusionLenacapavir 2109226-54-0 is a promising new antiretroviral drug that offers a unique mechanism of action and potential for long-acting treatment. Clinical trials have shown its safety and effectiveness against drug-resistant strains of HIV, making it a potential game-changer in the field of HIV/AIDS treatment.Quote InquiryContact us!

Introduction182182-31-6 | Exatecan Intermediate| Exatecan Intermediate is a popular chemical that has been used as a synthetic intermediate in the drug manufacturing industry. It is most commonly used as a starting material for exatecan mesylate, a drug that has been found useful in cancer treatment.What is 182182-31-6 | Exatecan Intermediate?182182-31-6 | Exatecan Intermediate is a chemical compound with the molecular formula C25H26N2O4. Its systematic name is 4-​oxo-​1H-​pyrrolo[3,​2-​c]​quinoline-​3-​carboxylic acid methyl ester. It is typically produced by the condensation of 2-quinolinecarboxylic acid with 3-amino-2-methylbenzoic acid.Applications182182-31-6 | Exatecan Intermediate is an important intermediate compound in the synthesis of various drug molecules that have potential applications in cancer treatment. It is most notably used in the production of exatecan mesylate, which is a drug that has shown remarkable effectiveness in the treatment of various types of cancer, including lung, breast, and ovarian cancer.Synthesis of Exatecan MesylateExatecan mesylate is synthesized from 182182-31-6 | Exatecan Intermediate by treating it with various reagents in a complex multi-step reaction. Exatecan mesylate is the final product, which is obtained after purifying and isolating it from the reaction mixture. The yield of exatecan mesylate obtained using 182182-31-6 | Exatecan Intermediate as the starting material is high, making it a preferred choice in large-scale drug production facilities.Properties182182-31-6 | Exatecan Intermediate is a pale yellow solid that is slightly soluble in water. It is highly soluble in organic solvents, such as methanol and acetonitrile. It has a molar mass of 418.48 g/mol and a melting point of 225°C. It is an intermediate product in the exatecan mesylate synthesis reaction and has no significant biological activity of its own.Stability and Storage182182-31-6 | Exatecan Intermediate should be stored in a cool, dry place away from direct sunlight. It is sensitive to air and moisture, and contact with either can result in degradation of the compound. It should be stored in an airtight container and under a blanket of inert gas, if possible, to prevent degradation. The shelf life of this compound is typically one year when stored under ideal conditions.Regulatory Status182182-31-6 | Exatecan Intermediate is a non-regulated substance and does not have any mandatory reporting requirements under the various chemical regulatory regimes. However, it is always important to comply with local regulatory requirements and follow appropriate safety protocols for handling chemicals.Conclusion182182-31-6 | Exatecan Intermediate is an important chemical intermediate in the drug manufacturing industry, particularly in the production of exatecan mesylate. It has various potential applications in cancer treatment and other therapeutic areas. Proper handling and storage of this substance are crucial to maintain its stability and quality.Quote InquiryContact us!

IntroductionExatecan Mesylate, also known as DX-8951, is a synthetic derivative of camptothecin, an alkaloid obtained from the bark of the Chinese tree Camptotheca acuminata. Exatecan Mesylate is a potent DNA topoisomerase I inhibitor, which means it can halt or slow down the replication of cancer cells. In this article, we will talk about the various aspects of CAS 169869-90-3 Exatecan Mesylate.Properties of Exatecan MesylateExatecan Mesylate has a molecular formula of C30H32ClN3O8S and a molecular weight of 647.11 g/mol. It is a light yellow powder that is soluble in water, methanol, and ethanol but insoluble in ethyl acetate and dichloromethane.Uses of Exatecan MesylateExatecan Mesylate has potential uses in cancer treatment. It has been shown to be effective against various types of cancer, including breast cancer, lung cancer, ovarian cancer, and pancreatic cancer. Additionally, it has been tested in clinical trials as a treatment for refractory and relapsed solid tumors.Mechanism of ActionAs mentioned before, Exatecan Mesylate works by inhibiting DNA topoisomerase I, an enzyme that is essential for DNA replication. When the cell tries to copy itself, topoisomerase I relieves tension in the DNA so that it can be unwound, copied, and then rewound. Without this activity, the DNA strands cannot be separated, and replication cannot occur, leading to cell death.StorageExatecan Mesylate should be stored in a cool, dry place at room temperature and protected from light. It should be stored away from any heat sources or strong oxidizing agents.Preparation and AdministrationExatecan Mesylate is available as a sterile lyophilized powder for injection. It should be prepared and administered only by a licensed healthcare provider with experience in handling chemotherapy drugs. The appropriate dosage and treatment schedule will depend on various factors, including the patient's medical history, age, weight, and the type and stage of cancer.Alternative NamesExatecan Mesylate is also known as DX-8951, LCK-893, and SJG-136.ConclusionIn conclusion, Exatecan Mesylate is a potent chemotherapy drug that is being explored as a potential treatment option for various types of cancer. Its mechanism of action and efficacy against solid tumors make it a promising drug in the fight against cancer.Quote InquiryContact us!

IntroductionBeraprost intermediate CAS: 2081187-29-1 is a chemical compound commonly used in the production of prostacyclin analogs. This compound is critical for the synthesis of beraprost sodium, a prescription medication used to treat peripheral artery disease. In this article, we will explore the different aspects of Beraprost intermediate CAS: 2081187-29-1, including its structure, synthesis, and applications.Structure of Beraprost intermediate CAS: 2081187-29-1Beraprost intermediate CAS: 2081187-29-1 has a molecular formula C27H35NO4. It has a molecular weight of 441.57 g/mol and a melting point of approximately 120-140°C.Synthesis of Beraprost intermediate CAS: 2081187-29-1The synthesis of Beraprost intermediate CAS: 2081187-29-1 involves several steps. The starting material is 2,3,6-trimethylphenol, which undergoes several chemical reactions, such as nitration, reduction, and acylation, to give the desired product.Uses and Applications of Beraprost intermediate CAS: 2081187-29-1Beraprost intermediate CAS: 2081187-29-1 is primarily used in the production of beraprost sodium, which is a medication used to treat peripheral artery disease. Beraprost sodium is also being studied for its potential therapeutic applications in other conditions, such as pulmonary arterial hypertension.Pharmacological Properties of Beraprost intermediate CAS: 2081187-29-1Beraprost intermediate CAS: 2081187-29-1 is a potent inhibitor of platelet aggregation. It also has vasodilatory and anti-inflammatory effects. These pharmacological properties are critical for the therapeutic effects of beraprost sodium.Safety and ToxicityThe safety and toxicity of Beraprost intermediate CAS: 2081187-29-1 have not been extensively studied. However, since this compound is used in the production of a prescription medication, it is subject to strict quality control and regulatory oversight.Storage and HandlingBeraprost intermediate CAS: 2081187-29-1 should be stored in a cool, dry place away from light and moisture. It should also be handled with caution since it is a chemical compound that can be hazardous if mishandled.Market and SuppliersBeraprost intermediate CAS: 2081187-29-1 is widely available from various chemical suppliers worldwide. The market for this compound is primarily driven by the demand for beraprost sodium, which is used to treat peripheral artery disease.ConclusionBeraprost intermediate CAS: 2081187-29-1 is a critical compound in the production of prostacyclin analogs, particularly beraprost sodium. This compound has pharmacological properties that are essential for the therapeutic effects of beraprost sodium. While its safety and toxicity have not been extensively studied, Beraprost intermediate CAS: 2081187-29-1 is subject to strict quality control and regulatory oversight.Contact us!

Beraprost CAS:88430-50-6 - Benefits, Uses and Side EffectsIf you are looking for a medication to treat pulmonary arterial hypertension, Beraprost is a great option for you. Beraprost is a prostacyclin analogue that helps to widen the blood vessels in the lungs and enhance blood flow. This medication is sold under the brand name of Tracleer and is available in tablet form. Here's everything you need to know about Beraprost CAS:88430-50-6.What is Beraprost?Beraprost is a prostacyclin analogue that is often used to treat pulmonary arterial hypertension or high blood pressure in the lungs. Beraprost helps to improve pulmonary hemodynamics by dilating the blood vessels, reducing inflammation, and increasing blood flow. This medication is available in tablet form and is sold under the brand name of Tracleer.How does Beraprost work?Beraprost works by activating prostanoid receptors and enhancing the activity of the cAMP signaling pathway. This activity leads to the dilation of the blood vessels, which reduces the pulmonary arterial pressure. By improving blood flow, Beraprost helps to reduce symptoms of pulmonary arterial hypertension like shortness of breath and fatigue.What are the benefits of Beraprost?The primary benefit of Beraprost is that it helps to improve pulmonary hemodynamics by dilating the blood vessels in the lungs. This results in increased blood flow to the lungs, which can help to reduce symptoms of pulmonary arterial hypertension. Beraprost is also beneficial in reducing inflammation and preventing the proliferation of smooth muscle cells.What are the uses of Beraprost?Beraprost is typically used to treat pulmonary arterial hypertension or high blood pressure in the lungs. It can also be used to improve exercise capacity and reduce pulmonary vascular resistance in patients with pulmonary hypertension. Beraprost has been studied in combination with other medications for the treatment of pulmonary arterial hypertension with promising results.What are the side effects of Beraprost?Some common side effects of Beraprost include headache, nausea, diarrhea, flushing, and edema. These side effects may go away on their own as your body adjusts to the medication. However, if you experience any severe side effects, it is important to contact your doctor right away.Who should not take Beraprost?Patients who are allergic to Beraprost or other ingredients in Tracleer should not take this medication. Beraprost may also interact with other medications such as beta-blockers, calcium channel blockers, and anticoagulants. It is important to inform your doctor of all medications you are taking before starting Beraprost.Can Beraprost be taken with food?Beraprost can be taken with or without food. However, it is recommended to take Beraprost at the same time every day to ensure consistent blood levels of the medication.ConclusionBeraprost is a prostacyclin analogue that is used to treat pulmonary arterial hypertension or high blood pressure in the lungs. It helps to improve pulmonary hemodynamics by dilating the blood vessels, reducing inflammation, and increasing blood flow. Beraprost is generally safe when taken as prescribed, but it may cause side effects in some individuals. If you are considering taking Beraprost, it is important to discuss the risks and benefits with your doctor.Contact us!

The Basics of Orforglipron intermediate CAS 2212021-61-7Orforglipron intermediate CAS 2212021-61-7 is a chemical compound that is widely used in the pharmaceutical industry. It is part of a group of compounds known as oxazolidinones, which feature a five-membered ring that includes both nitrogen and oxygen atoms. This intermediate may also be referred to as (S)-3-(tert-butoxycarbonylamino)-2-oxo-1-(phenylmethyl)azetidine-1-carboxylic acid.The Chemical Properties of Orforglipron Intermediate CAS 2212021-61-7The chemical formula for Orforglipron intermediate CAS 2212021-61-7 is C18H22N2O5. It has a molecular weight of 354.387 g/mol and a melting point of 160-161°C. This intermediate is a white or off-white crystal that is soluble in chloroform, methanol, and other organic solvents.Orforglipron Intermediate CAS 2212021-61-7 UsesOrforglipron intermediate CAS 2212021-61-7 is used in the production of Orforglimprone, a potent antibiotic used to treat a variety of bacterial infections. Moreover, this intermediate can be used to synthesize a wide range of organic compounds and APIs in the pharmaceutical industry.Handling and Storage of Orforglipron Intermediate CAS 2212021-61-7Orforglipron intermediate CAS 2212021-61-7 should be handled with care and stored in a cool, dry place away from heat and light sources. It should be kept in sealed containers to prevent exposure to moisture and air. Proper PPE should be used when handling this intermediate as it can irritate the skin, eyes, and respiratory system if not handled properly.The Future of Orforglipron Intermediate CAS 2212021-61-7As the demand for new and more effective antibiotics grows, the market for Orforglipron intermediate CAS 2212021-61-7 is set to expand. There is also increasing interest in the use of this compound as a starting material in the production of a wide range of organic molecules used in the manufacture of pharmaceuticals.Where to Find Orforglipron Intermediate CAS 2212021-61-7Orforglipron intermediate CAS 2212021-61-7 can be purchased from chemical suppliers and pharmaceutical intermediates distributors worldwide. It is important to choose a reliable supplier who offers high-quality products and reliable customer support.ConclusionOrforglipron intermediate CAS 2212021-61-7 is an important chemical intermediate used in the synthesis of a wide range of pharmaceuticals, including antibiotics. It poses potential risks to human safety and must be handled with care. With increasing demand in the pharmaceutical market, the future looks promising for compounds like Orforglipron intermediate CAS 2212021-61-7.Quote InquiryContact us!

Introduction2212021-83-3 - Orforglipron intermediate is a chemical compound commonly used in the pharmaceutical industry. This compound serves as an important intermediate for the synthesis of Orforglipron, a drug used to treat various bacterial infections. In this article, we will examine the various aspects of 2212021-83-3 - Orforglipron intermediate and its significance.Chemical Properties2212021-83-3 - Orforglipron intermediate is a crystalline solid with a molecular weight of 418.44 g/mol. It is sparingly soluble in water but dissolves well in organic solvents. This intermediate contains a carboxylic acid group and a pyrazole ring that are essential for the synthesis of Orforglipron.SynthesisThe synthesis of 2212021-83-3 - Orforglipron intermediate involves several steps. The process begins with the reaction between 2,3-dimethyl-4-nitroquinolone and hydrazine hydrate to form 2,3-dimethyl-4-nitropyrazole. The nitro group in this compound is then reduced to an amino group to create 2,3-dimethyl-4-aminopyrazole. The final step involves the esterification of 2,3-dimethyl-4-aminopyrazole with ethyl 2-(2-chloroethyl)-4-methylthiazole-5-carboxylate to produce 2212021-83-3 - Orforglipron intermediate.Uses2212021-83-3 - Orforglipron intermediate is primarily used as a key intermediate in the synthesis of Orforglipron, which is a broad-spectrum antibiotic drug used to treat bacterial infections. Orforglipron is particularly effective in treating antibiotic-resistant strains of bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE).SafetyThe safety of 2212021-83-3 - Orforglipron intermediate has not been extensively studied. However, it is important to handle this compound with caution as it is potentially hazardous. Avoid prolonged exposure to this compound and take appropriate safety measures when handling it.Storage2212021-83-3 - Orforglipron intermediate should be stored in a cool, dry place away from sources of heat and light. This compound should be kept in an airtight container to prevent contamination.Conclusion2212021-83-3 - Orforglipron intermediate is a crucial compound in the synthesis of Orforglipron, a potent antibiotic drug used to treat bacterial infections. With its unique chemical properties and synthesis method, this compound plays an essential role in the pharmaceutical industry.Quote InquiryContact us!

IntroductionWhen it comes to the production of innovative drugs, intermediates play a crucial role. These are compounds that are used in the synthesis of active pharmaceutical ingredients (APIs). One such intermediate is 2189684-53-3, also known as Lenacapavir intermediate. In this article, we will explore the various aspects of this important compound and its significance in the pharmaceutical industry.Chemical Properties2189684-53-3 is a chemical compound with the molecular formula C14H16F3N3O4S. It has a molecular weight of 385.35 g/mol and its CAS (Chemical Abstracts Service) number is 2189684-53-3. The compound has a white to off-white crystalline powder appearance, and it is sparingly soluble in water.Synthesis2189684-53-3 is synthesized by a multi-step process that involves the reaction of several intermediate compounds. The process starts with the reaction of 2,4-difluorobenzonitrile and ethyl 2-(2-aminoethoxy)acetate in the presence of a base, which yields the first intermediate. The subsequent steps involve the reaction of this intermediate with other compounds such as sodium hydride, thionyl chloride, and acetic anhydride to produce the final product.UsesThe primary use of 2189684-53-3 is as an intermediate in the production of Lenacapavir, an HIV-1 capsid inhibitor. This drug is currently in clinical trials and has shown promising results in reducing the viral load in HIV patients. 2189684-53-3 is also used in the production of other pharmaceuticals that require a similar chemical structure.Quality StandardsIn the pharmaceutical industry, the quality of intermediates like 2189684-53-3 is crucial for the efficient production of APIs and ensures the safety and efficacy of the final drug product. The compound is expected to meet various quality standards such as USP, EP, and JP. The purity of the compound should be above 99%, and its impurities should be within acceptable limits.Storage and Handling2189684-53-3 should be stored in a cool and dry place, away from light and moisture. It should be handled with care, and precautions such as lab coats, gloves, and goggles should be taken while handling the compound. It is recommended to perform the handling and synthesis in a well-ventilated area.Regulatory StatusThe production and use of 2189684-53-3 are subject to regulatory guidelines and standards set by various agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The compound is not approved for use as a drug in any country and is only used as an intermediate in drug production.Risks and Safety2189684-53-3 is considered to be a low-risk compound when handled and used appropriately. However, it can cause skin irritation and eye irritation upon contact. In case of skin or eye contact, the affected area should be washed with plenty of water for several minutes. If the irritation persists, medical attention should be sought immediately.Environmental ImpactThe impact of 2189684-53-3 on the environment is not well studied. However, it is considered a low hazard to the environment and should be handled and disposed of in accordance with local environmental regulations.ConclusionIn conclusion, 2189684-53-3 is an important intermediate in the production of Lenacapavir and other pharmaceuticals. Its chemical properties, synthesis, uses, quality standards, storage and handling, regulatory status, risks and safety, and environmental impact are crucial aspects that need to be taken into consideration while handling and using the compound.Contact us!